FHIRsmith: DocumentReference/DocumentReference-asm-carbamazepine-test-script-1.json

FHIR IG analytics

Package	hl7.eu.fhir.gh
Resource Type	DocumentReference
Id	DocumentReference-asm-carbamazepine-test-script-1.json
FHIR Version	R5

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: DocumentReference asm-carbamazepine-test-script-1

Profile: Additional Support Material Profile

RelatedMedicalIssue: Human immunodeficiency virus infection (disorder)

identifier: http://example.org/testscript7

version: 1.0

status: Current

docStatus: Final

category: Medication and Disease Management

subject: MedicinalProductDefinition: identifier = https://spor.ema.europa.eu/pmswi#39.955,https://www.who-umc.org/phpid_4#FB9808F4FED210183F412F9998622287,https://www.who-umc.org/phpid_3#5C62673C79E096D37914D32A45AA8F4D; type = Medicinal Product; domain = Human use; status = active; legalStatusOfSupply = Medicinal product subject to medical prescription

author: National Alliance on Mental Illness

description:

Additional Information for Carbamazepine and Depression

content
Attachments
- Extension ContentType Language Url Title
* text/html English https://www.nami.org/about-mental-illness/treatments/mental-health-medications/types-of-medication/carbamazepine-tegretol/ Additional Information for Carbamazepine and Depression

Source1

{
  "resourceType": "DocumentReference",
  "id": "asm-carbamazepine-test-script-1",
  "meta": {
    "profile": [
      "http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/AdditionalSupportMaterial"
    ]
  },
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/RelatedMedicalIssue",
      "valueCodeableReference": {
        "concept": {
          "coding": [
            {
              "system": "http://snomed.info/sct",
              "code": "86406008",
              "display": "Human immunodeficiency virus infection (disorder)"
            }
          ]
        }
      }
    }
  ],
  "identifier": [
    {
      "system": "http://example.org",
      "value": "testscript7"
    }
  ],
  "version": "1.0",
  "status": "current",
  "docStatus": "final",
  "category": [
    {
      "coding": [
        {
          "system": "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/asm-category-cs",
          "code": "MDM"
        }
      ]
    }
  ],
  "subject": {
    "reference": "MedicinalProductDefinition/mpac2bb08bb4cc3f51f8c4e3513034c019"
  },
  "author": [
    {
      "display": "National Alliance on Mental Illness"
    }
  ],
  "description": "Additional Information for Carbamazepine and Depression",
  "content": [
    {
      "attachment": {
        "extension": [
          {
            "url": "http://hl7.eu/fhir/ig/gravitate-health/StructureDefinition/VisualizationMethod",
            "valueCode": "URL"
          }
        ],
        "contentType": "text/html",
        "language": "en",
        "url": "https://www.nami.org/about-mental-illness/treatments/mental-health-medications/types-of-medication/carbamazepine-tegretol/",
        "title": "Additional Information for Carbamazepine and Depression"
      }
    }
  ]
}